Eupatilin

22368-21-4

C18H16O7

H2O : < 0.1 mg/mL (insoluble); DMSO : 50 mg/mL (145.21 mM; Need ultrasonic)

Cell Cycle/DNA Damage; Autophagy

Eupatilin, a lipophilic flavonoid isolated from Artemisia species, is a PPARalpha agonist, and possesses anti-apoptotic, anti-oxidative and anti-inflammatory activities. IC50 & Target: PPAR^[1] In Vitro: Eupatilin is a PPARalpha agonist. Eupatilin (10, 30, 100 uM) suppresses IL-4 expression and degranulation in RBL-2H3 cells^[1]. Eupatilin (50-100 uM) slightly reduces cell viability of HaCaT cells. Eupatilin (10, 30, 50, 100 uM) increases PPARalpha transactivation and expression in HaCaT cells. Eupatilin (10, 30, 50 uM) also suppresses TNFalpha-induced MMP-2/-9 expression in HaCaT cells. Furthermore, Eupatilin inhibits TNFalpha-induced p65 translocation, IkappaBalpha Phosphorylation, AP-1 and MAPK signaling via PPARalpha^[2]. Eupatilin (10-50 uM) shows no cytotoxic effects on ARPE19 cells. Eupatilin (10, 25, 50 uM) elevates cell viability from oxidative stress, and inhibits H₂O₂-induced ROS production in ARPE19 cells. Moreover, Eupatilin (50 uM) inbibits H₂O₂-induced cells apoptosis and promotes the activation of PI3K/Akt pathway in RPE cells^[3]. In Vivo: Eupatilin (1.5% or 3.0%) restores PPARalpha mRNA expression, and improves atopic dermatitis (AD)-like symptoms in oxazolone-induced Balb/c mice. Eupatilin causes significant decrease in serum IgE, IL-4 levels, oxazolone-induced TNFalpha, IFNgamma, IL-1beta, TSLP, IL-33 and IL-25 mRNA expression in oxazolone-induced mice. Eupatilin also increases filaggrin and loricrin mRNA expression in oxazolone-induced mice^[1].